Clinical Trial Update: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase III randomized trial evaluating orelabrutinib plus R-CHOP versus R-CHOP alone in treatment-naïve mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Orelabrutinib (orelabrutinib)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Treatment-naїve Mantle Cell Lymphoma | Phase 3 | Status: COMPLETED